{"title":"Plasmablastic lymphoma presenting as sino-nasal mass in a child: a case report","authors":"Arjun Kachhwaha, Kavya Ronanki, Prisla Maria Dalton, Nikhil Nagpal, Uttam Kumar Nath","doi":"10.1016/j.phoj.2025.04.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Plasmablastic lymphoma (PBL) is a very aggressive non-Hodgkin lymphoma that mostly occurs in immunocompromised individuals, especially those affected with human immunodeficiency virus (HIV) infection, and is rarely reported in children.</div></div><div><h3>Case presentation</h3><div>An 8-year-old female case of HIV on highly active antiretroviral therapy (HAART) for the last 2 years presented with epistaxis, and a left sino-nasal mass for the last 6 months and a rapidly progressing left orbital mass for one month. Endoscopic debulking surgery revealed the diagnosis of PBL. She was managed with CODOX-M (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate) alternating with IVAC (ifosfamide, etoposide, and high-dose cytarabine) for 2 cycles each. The patient achieved complete morphological remission, confirmed on positron emission tomography-computed tomography (PET/CT) and local radiation was then given. HAART was withheld temporarily during the CODOX-M cycle owing to significant drug interaction and liver toxicity but continued during IVAC. The patient has been in remission for the 13 months following completion of therapy.</div></div><div><h3>Conclusion</h3><div>PBL is an aggressive disease that requires intensive chemotherapy. It is challenging to monitor adverse effects and drug-drug interaction while on chemotherapy and HAART together. Close monitoring and follow-up are needed, as over half of patients will relapse post-remission.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 2","pages":"Article 100449"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124525000178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Plasmablastic lymphoma (PBL) is a very aggressive non-Hodgkin lymphoma that mostly occurs in immunocompromised individuals, especially those affected with human immunodeficiency virus (HIV) infection, and is rarely reported in children.
Case presentation
An 8-year-old female case of HIV on highly active antiretroviral therapy (HAART) for the last 2 years presented with epistaxis, and a left sino-nasal mass for the last 6 months and a rapidly progressing left orbital mass for one month. Endoscopic debulking surgery revealed the diagnosis of PBL. She was managed with CODOX-M (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate) alternating with IVAC (ifosfamide, etoposide, and high-dose cytarabine) for 2 cycles each. The patient achieved complete morphological remission, confirmed on positron emission tomography-computed tomography (PET/CT) and local radiation was then given. HAART was withheld temporarily during the CODOX-M cycle owing to significant drug interaction and liver toxicity but continued during IVAC. The patient has been in remission for the 13 months following completion of therapy.
Conclusion
PBL is an aggressive disease that requires intensive chemotherapy. It is challenging to monitor adverse effects and drug-drug interaction while on chemotherapy and HAART together. Close monitoring and follow-up are needed, as over half of patients will relapse post-remission.